10-K Filing

HUMANA INC CIK: 49071 FY 2022

Filing Information

Form Type	10-K
Accession Number	`0000049071-23-000011`
Period End Date	20221231
Filing Date	20230216
Fiscal Year	2022
Fiscal Period	FY
XBRL Instance	hum-20221231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 83 Income Statement 60 Cash Flow Statement 140 Stockholders Equity 33 Comprehensive Income 30

Balance Sheet 83 line items

Line Item	Tag	Value	Unit	Period
Receivables, allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$70.00M	USD	Point-in-time
Receivables, allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$83.00M	USD	Point-in-time
Preferred stock, par (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$1.00	USD	Point-in-time
Preferred stock, par (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$1.00	USD	Point-in-time
Preferred stock, authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, authorized (in shares)	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.06B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.39B	USD	Point-in-time
Investment securities	`ShortTermInvestments`	$13.88B	USD	Point-in-time
Investment securities	`ShortTermInvestments`	$13.19B	USD	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Common stock, par (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.17	USD	Point-in-time
Receivables, net of allowances of $70 in 2022 and $83 in 2021	`ReceivablesNetCurrent`	$1.67B	USD	Point-in-time
Common stock, par (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.17	USD	Point-in-time
Receivables, net of allowances of $70 in 2022 and $83 in 2021	`ReceivablesNetCurrent`	$1.81B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$6.49B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$5.57B	USD	Point-in-time
Common stock, authorized (in shares)	`CommonStockSharesAuthorized`	300.00M	shares	Point-in-time
Common stock, authorized (in shares)	`CommonStockSharesAuthorized`	300.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$26.18B	USD	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	198.67M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$24.89B	USD	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	198.65M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.22B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	73.69M	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	69.85M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.07B	USD	Point-in-time
Long-term investment securities	`AvailableForSaleSecuritiesDebtSecuritiesNoncurrent`	$780.00M	USD	Point-in-time
Long-term investment securities	`AvailableForSaleSecuritiesDebtSecuritiesNoncurrent`	$380.00M	USD	Point-in-time
Goodwill	`Goodwill`	$11.09B	USD	Point-in-time
Goodwill	`Goodwill`	$4.45B	USD	Point-in-time
Goodwill	`Goodwill`	$9.14B	USD	Point-in-time
Equity method investments	`EquityMethodInvestments`	$141.00M	USD	Point-in-time
Equity method investments	`EquityMethodInvestments`	$749.00M	USD	Point-in-time
Other long-term assets	`OtherAssetsNoncurrent`	$3.38B	USD	Point-in-time
Other long-term assets	`OtherAssetsNoncurrent`	$4.38B	USD	Point-in-time
Total assets	`Assets`	$44.36B	USD	Point-in-time
Total assets	`Assets`	$43.05B	USD	Point-in-time
Benefits payable	`LiabilityForClaimsAndClaimsAdjustmentExpense`	$6.00B	USD	Point-in-time
Benefits payable	`LiabilityForClaimsAndClaimsAdjustmentExpense`	$9.26B	USD	Point-in-time
Benefits payable	`LiabilityForClaimsAndClaimsAdjustmentExpense`	$8.14B	USD	Point-in-time
Benefits payable	`LiabilityForClaimsAndClaimsAdjustmentExpense`	$8.29B	USD	Point-in-time
Trade accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$4.51B	USD	Point-in-time
Trade accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$5.24B	USD	Point-in-time
Book overdraft	`BookOverdraftLiability`	$326.00M	USD	Point-in-time
Book overdraft	`BookOverdraftLiability`	$298.00M	USD	Point-in-time
Unearned revenues	`ContractWithCustomerLiabilityCurrent`	$254.00M	USD	Point-in-time
Unearned revenues	`ContractWithCustomerLiabilityCurrent`	$286.00M	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.09B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.95B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.18B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$15.33B	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$10.54B	USD	Point-in-time
Long-term debt	`LongTermDebtNoncurrent`	$9.03B	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.47B	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.38B	USD	Point-in-time
Total liabilities	`Liabilities`	$27.68B	USD	Point-in-time
Total liabilities	`Liabilities`	$28.25B	USD	Point-in-time
Commitments and contingencies (Note 17)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 17)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $1 par; 10,000,000 shares authorized; none issued	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $1 par; 10,000,000 shares authorized; none issued	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,666,598 shares issued at December 31, 2022 and 198,648,742 shares issued at December 31, 2021	`CommonStockValue`	$33.00M	USD	Point-in-time
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,666,598 shares issued at December 31, 2022 and 198,648,742 shares issued at December 31, 2021	`CommonStockValue`	$33.00M	USD	Point-in-time
Capital in excess of par value	`AdditionalPaidInCapitalCommonStock`	$3.25B	USD	Point-in-time
Capital in excess of par value	`AdditionalPaidInCapitalCommonStock`	$3.08B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$25.49B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$23.09B	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$42.00M	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.30B	USD	Point-in-time
Treasury stock, at cost, 73,691,955 shares at December 31, 2022 and 69,846,758 shares at December 31, 2021	`TreasuryStockCommonValue`	$12.16B	USD	Point-in-time
Treasury stock, at cost, 73,691,955 shares at December 31, 2022 and 69,846,758 shares at December 31, 2021	`TreasuryStockCommonValue`	$10.16B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$15.31B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$16.08B	USD	Point-in-time
Noncontrolling interests	`MinorityInterest`	$59.00M	USD	Point-in-time
Noncontrolling interests	`MinorityInterest`	$23.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.10B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.37B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.04B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.73B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$43.05B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$44.36B	USD	Point-in-time

Income Statement 60 line items

Line Item	Tag	Value	Unit	Period
Premiums	`PremiumsEarnedNet`	$87.71B	USD	Annual
Premiums	`PremiumsEarnedNet`	$79.82B	USD	Annual
Premiums	`PremiumsEarnedNet`	$74.19B	USD	Annual
Services	`RevenueFromContractWithCustomerIncludingAssessedTax`	$3.06B	USD	Annual
Services	`RevenueFromContractWithCustomerIncludingAssessedTax`	$1.81B	USD	Annual
Services	`RevenueFromContractWithCustomerIncludingAssessedTax`	$4.78B	USD	Annual
Investment income	`InvestmentIncomeInterestAndDividend`	$187.00M	USD	Annual
Investment income	`InvestmentIncomeInterestAndDividend`	$382.00M	USD	Annual
Investment income	`InvestmentIncomeInterestAndDividend`	$1.15B	USD	Annual
Total revenues	`Revenues`	$92.87B	USD	Annual
Total revenues	`Revenues`	$83.06B	USD	Annual
Total revenues	`Revenues`	$77.16B	USD	Annual
Benefits	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$69.20B	USD	Annual
Benefits	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$61.63B	USD	Annual
Benefits	`PolicyholderBenefitsAndClaimsIncurredHealthCare`	$75.69B	USD	Annual
Operating costs	`SellingGeneralAndAdministrativeExpense`	$10.05B	USD	Annual
Operating costs	`SellingGeneralAndAdministrativeExpense`	$10.12B	USD	Annual
Operating costs	`SellingGeneralAndAdministrativeExpense`	$12.67B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortizationIncomeStatement`	$489.00M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortizationIncomeStatement`	$709.00M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortizationIncomeStatement`	$596.00M	USD	Annual
Total operating expenses	`BenefitsLossesAndExpenses`	$72.17B	USD	Annual
Total operating expenses	`BenefitsLossesAndExpenses`	$79.92B	USD	Annual
Total operating expenses	`BenefitsLossesAndExpenses`	$89.07B	USD	Annual
Income from operations	`OperatingIncomeLoss`	$3.80B	USD	Annual
Income from operations	`OperatingIncomeLoss`	$3.15B	USD	Annual
Income from operations	`OperatingIncomeLoss`	$4.99B	USD	Annual
Gain on sale of KAH Hospice	`GainLossOnSaleOfBusiness`	$237.00M	USD	Annual
Gain on sale of KAH Hospice	`GainLossOnSaleOfBusiness`	-	USD	Annual
Gain on sale of KAH Hospice	`GainLossOnSaleOfBusiness`	-	USD	Annual
Interest expense	`InterestExpense`	$401.00M	USD	Annual
Interest expense	`InterestExpense`	$326.00M	USD	Annual
Interest expense	`InterestExpense`	$283.00M	USD	Annual
Other expense (income), net	`OtherNonoperatingIncomeExpense`	$-103.00M	USD	Annual
Other expense (income), net	`OtherNonoperatingIncomeExpense`	$-68.00M	USD	Annual
Other expense (income), net	`OtherNonoperatingIncomeExpense`	$532.00M	USD	Annual
Income before income taxes and equity in net (losses) earnings	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$4.60B	USD	Annual
Income before income taxes and equity in net (losses) earnings	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$3.57B	USD	Annual
Income before income taxes and equity in net (losses) earnings	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$3.35B	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$485.00M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$762.00M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$1.31B	USD	Annual
Equity in net (losses) earnings	`IncomeLossFromEquityMethodInvestments`	$65.00M	USD	Annual
Equity in net (losses) earnings	`IncomeLossFromEquityMethodInvestments`	$74.00M	USD	Annual
Equity in net (losses) earnings	`IncomeLossFromEquityMethodInvestments`	$-4.00M	USD	Annual
Net income	`ProfitLoss`	$2.93B	USD	Annual
Net income	`ProfitLoss`	$2.80B	USD	Annual
Net income	`ProfitLoss`	$3.37B	USD	Annual
Net loss (income) attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$1.00M	USD	Annual
Net loss (income) attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	Annual
Net loss (income) attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-4.00M	USD	Annual
Net income attributable to Humana	`NetIncomeLoss`	$3.37B	USD	Annual
Net income attributable to Humana	`NetIncomeLoss`	$2.81B	USD	Annual
Net income attributable to Humana	`NetIncomeLoss`	$2.93B	USD	Annual
Basic earnings per common share (in dollars per share)	`EarningsPerShareBasic`	$25.47	USD	Annual
Basic earnings per common share (in dollars per share)	`EarningsPerShareBasic`	$22.79	USD	Annual
Basic earnings per common share (in dollars per share)	`EarningsPerShareBasic`	$22.20	USD	Annual
Diluted earnings per common share (in dollars per share)	`EarningsPerShareDiluted`	$25.31	USD	Annual
Diluted earnings per common share (in dollars per share)	`EarningsPerShareDiluted`	$22.08	USD	Annual
Diluted earnings per common share (in dollars per share)	`EarningsPerShareDiluted`	$22.67	USD	Annual

Cash Flow Statement 140 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$2.93B	USD	Annual
Net income	`ProfitLoss`	$2.80B	USD	Annual
Net income	`ProfitLoss`	$3.37B	USD	Annual
Gain on sale of KAH Hospice	`GainLossOnSaleOfBusiness`	-	USD	Annual
Gain on sale of KAH Hospice	`GainLossOnSaleOfBusiness`	$237.00M	USD	Annual
Gain on sale of KAH Hospice	`GainLossOnSaleOfBusiness`	-	USD	Annual
Loss (gain) on investment securities, net	`DebtAndEquitySecuritiesGainLoss`	$-130.00M	USD	Annual
Loss (gain) on investment securities, net	`DebtAndEquitySecuritiesGainLoss`	$838.00M	USD	Annual
Loss (gain) on investment securities, net	`DebtAndEquitySecuritiesGainLoss`	$-205.00M	USD	Annual
Gain on Kindred at Home equity method investment	`EquityMethodInvestmentRealizedGainLossOnDisposal`	$1.13B	USD	Annual
Gain on Kindred at Home equity method investment	`EquityMethodInvestmentRealizedGainLossOnDisposal`	-	USD	Annual
Gain on Kindred at Home equity method investment	`EquityMethodInvestmentRealizedGainLossOnDisposal`	-	USD	Annual
Equity in net losses (earnings)	`IncomeLossFromEquityMethodInvestments`	$74.00M	USD	Annual
Equity in net losses (earnings)	`IncomeLossFromEquityMethodInvestments`	$-4.00M	USD	Annual
Equity in net losses (earnings)	`IncomeLossFromEquityMethodInvestments`	$65.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$181.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$180.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$216.00M	USD	Annual
Depreciation	`Depreciation`	$749.00M	USD	Annual
Depreciation	`Depreciation`	$640.00M	USD	Annual
Depreciation	`Depreciation`	$528.00M	USD	Annual
Amortization	`AdjustmentForAmortization`	$73.00M	USD	Annual
Amortization	`AdjustmentForAmortization`	$88.00M	USD	Annual
Amortization	`AdjustmentForAmortization`	$96.00M	USD	Annual
Impairment of property and equipment	`TangibleAssetImpairmentCharges`	-	USD	Annual
Impairment of property and equipment	`TangibleAssetImpairmentCharges`	-	USD	Annual
Impairment of property and equipment	`TangibleAssetImpairmentCharges`	$248.00M	USD	Annual
(Benefit) provision for deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-100.00M	USD	Annual
(Benefit) provision for deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$195.00M	USD	Annual
(Benefit) provision for deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$15.00M	USD	Annual
Receivables	`IncreaseDecreaseInReceivables`	$85.00M	USD	Annual
Receivables	`IncreaseDecreaseInReceivables`	$54.00M	USD	Annual
Receivables	`IncreaseDecreaseInReceivables`	$280.00M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$491.00M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$463.00M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$581.00M	USD	Annual
Benefits payable	`IncreaseDecreaseInHealthCareInsuranceLiabilities`	$2.14B	USD	Annual
Benefits payable	`IncreaseDecreaseInHealthCareInsuranceLiabilities`	$104.00M	USD	Annual
Benefits payable	`IncreaseDecreaseInHealthCareInsuranceLiabilities`	$975.00M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$176.00M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$44.00M	USD	Annual
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$599.00M	USD	Annual
Unearned revenues	`IncreaseDecreaseInContractWithCustomerLiability`	$-65.00M	USD	Annual
Unearned revenues	`IncreaseDecreaseInContractWithCustomerLiability`	$32.00M	USD	Annual
Unearned revenues	`IncreaseDecreaseInContractWithCustomerLiability`	$71.00M	USD	Annual
Other, net	`OtherOperatingActivitiesCashFlowStatement`	$70.00M	USD	Annual
Other, net	`OtherOperatingActivitiesCashFlowStatement`	$40.00M	USD	Annual
Other, net	`OtherOperatingActivitiesCashFlowStatement`	$49.00M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$4.59B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$2.26B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$5.64B	USD	Annual
Proceeds from sale of KAH Hospice, net	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	$2.70B	USD	Annual
Proceeds from sale of KAH Hospice, net	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	-	USD	Annual
Proceeds from sale of KAH Hospice, net	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	-	USD	Annual
Acquisitions, net of cash and cash equivalents acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$337.00M	USD	Annual
Acquisitions, net of cash and cash equivalents acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$709.00M	USD	Annual
Acquisitions, net of cash and cash equivalents acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$4.19B	USD	Annual
Purchases of property and equipment, net	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.12B	USD	Annual
Purchases of property and equipment, net	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.32B	USD	Annual
Purchases of property and equipment, net	`PaymentsToAcquirePropertyPlantAndEquipment`	$964.00M	USD	Annual
Purchases of investment securities	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$9.12B	USD	Annual
Purchases of investment securities	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$6.05B	USD	Annual
Purchases of investment securities	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$7.20B	USD	Annual
Maturities of investment securities	`ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities`	$2.60B	USD	Annual
Maturities of investment securities	`ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities`	$1.36B	USD	Annual
Maturities of investment securities	`ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities`	$4.99B	USD	Annual
Proceeds from sales of investment securities	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$2.75B	USD	Annual
Proceeds from sales of investment securities	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$2.43B	USD	Annual
Proceeds from sales of investment securities	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$3.55B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-6.56B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-3.06B	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.01B	USD	Annual
Receipts (withdrawals) from contract deposits, net	`PaymentsForProceedsFromContractDeposits`	$-1.99B	USD	Annual
Receipts (withdrawals) from contract deposits, net	`PaymentsForProceedsFromContractDeposits`	$939.00M	USD	Annual
Receipts (withdrawals) from contract deposits, net	`PaymentsForProceedsFromContractDeposits`	$306.00M	USD	Annual
Proceeds from issuance of senior notes, net	`ProceedsFromIssuanceOfSeniorLongTermDebt`	$1.98B	USD	Annual
Proceeds from issuance of senior notes, net	`ProceedsFromIssuanceOfSeniorLongTermDebt`	$2.98B	USD	Annual
Proceeds from issuance of senior notes, net	`ProceedsFromIssuanceOfSeniorLongTermDebt`	$1.09B	USD	Annual
Repayment of senior notes	`RepaymentsOfSeniorDebt`	$400.00M	USD	Annual
Repayment of senior notes	`RepaymentsOfSeniorDebt`	$1.00B	USD	Annual
Repayment of senior notes	`RepaymentsOfSeniorDebt`	-	USD	Annual
(Repayments) proceeds from issuance of commercial paper, net	`ProceedsFromRepaymentsOfCommercialPaper`	$295.00M	USD	Annual
(Repayments) proceeds from issuance of commercial paper, net	`ProceedsFromRepaymentsOfCommercialPaper`	$-376.00M	USD	Annual
(Repayments) proceeds from issuance of commercial paper, net	`ProceedsFromRepaymentsOfCommercialPaper`	$352.00M	USD	Annual
Proceeds from term loan	`ProceedsFromNotesPayable`	$1.00B	USD	Annual
Proceeds from term loan	`ProceedsFromNotesPayable`	-	USD	Annual
Proceeds from term loan	`ProceedsFromNotesPayable`	$2.50B	USD	Annual
Repayment of term loan	`RepaymentsOfNotesPayable`	$2.00B	USD	Annual
Repayment of term loan	`RepaymentsOfNotesPayable`	$1.00B	USD	Annual
Repayment of term loan	`RepaymentsOfNotesPayable`	$2.08B	USD	Annual
Debt issue costs	`PaymentsOfDebtIssuanceCosts`	-	USD	Annual
Debt issue costs	`PaymentsOfDebtIssuanceCosts`	$6.00M	USD	Annual
Debt issue costs	`PaymentsOfDebtIssuanceCosts`	$31.00M	USD	Annual
Common stock repurchases	`PaymentsForRepurchaseOfCommonStock`	$79.00M	USD	Annual
Common stock repurchases	`PaymentsForRepurchaseOfCommonStock`	$1.82B	USD	Annual
Common stock repurchases	`PaymentsForRepurchaseOfCommonStock`	$2.10B	USD	Annual
Dividends paid	`PaymentsOfDividends`	$392.00M	USD	Annual
Dividends paid	`PaymentsOfDividends`	$354.00M	USD	Annual
Dividends paid	`PaymentsOfDividends`	$323.00M	USD	Annual
Change in book overdraft	`IncreaseDecreaseInBookOverdrafts`	$-28.00M	USD	Annual
Change in book overdraft	`IncreaseDecreaseInBookOverdrafts`	$6.00M	USD	Annual
Change in book overdraft	`IncreaseDecreaseInBookOverdrafts`	$95.00M	USD	Annual
Other, net	`ProceedsFromPaymentsForOtherFinancingActivities`	$9.00M	USD	Annual
Other, net	`ProceedsFromPaymentsForOtherFinancingActivities`	$49.00M	USD	Annual
Other, net	`ProceedsFromPaymentsForOtherFinancingActivities`	$21.00M	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.91B	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.02B	USD	Annual
Net cash (used in) provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.96B	USD	Annual
Increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.67B	USD	Annual
Increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$619.00M	USD	Annual
Increase (decrease) in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.28B	USD	Annual
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.05B	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.39B	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.06B	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.67B	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.05B	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$3.39B	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.06B	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$4.67B	USD	Point-in-time
Interest payments	`InterestPaidNet`	$285.00M	USD	Annual
Interest payments	`InterestPaidNet`	$258.00M	USD	Annual
Interest payments	`InterestPaidNet`	$354.00M	USD	Annual
Income tax payments, net	`IncomeTaxesPaidNet`	$1.13B	USD	Annual
Income tax payments, net	`IncomeTaxesPaidNet`	$758.00M	USD	Annual
Income tax payments, net	`IncomeTaxesPaidNet`	$227.00M	USD	Annual
Fair value of assets acquired, net of cash acquired	`FairValueOfAssetsAcquired`	$9.80B	USD	Annual
Fair value of assets acquired, net of cash acquired	`FairValueOfAssetsAcquired`	$819.00M	USD	Annual
Fair value of assets acquired, net of cash acquired	`FairValueOfAssetsAcquired`	$460.00M	USD	Annual
Less: Fair value of liabilities assumed	`LiabilitiesAssumed1`	$110.00M	USD	Annual
Less: Fair value of liabilities assumed	`LiabilitiesAssumed1`	$3.23B	USD	Annual
Less: Fair value of liabilities assumed	`LiabilitiesAssumed1`	$70.00M	USD	Annual
Less: Noncontrolling interests acquired	`NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired`	-	USD	Annual
Less: Noncontrolling interests acquired	`NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired`	$53.00M	USD	Annual
Less: Noncontrolling interests acquired	`NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired`	$22.00M	USD	Annual
Less: Remeasured existing Kindred at Home equity method investment	`NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment`	-	USD	Annual
Less: Remeasured existing Kindred at Home equity method investment	`NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment`	-	USD	Annual
Less: Remeasured existing Kindred at Home equity method investment	`NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment`	$2.36B	USD	Annual
Cash paid for acquired businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$709.00M	USD	Annual
Cash paid for acquired businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$337.00M	USD	Annual
Cash paid for acquired businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$4.19B	USD	Annual

Stockholders Equity 33 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.10B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.37B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.04B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.73B	USD	Point-in-time
Net income	`ProfitLoss`	$2.93B	USD	Annual
Net income	`ProfitLoss`	$2.80B	USD	Annual
Net income	`ProfitLoss`	$3.37B	USD	Annual
Distribution to noncontrolling interest holders, net	`NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders`	$-1.00M	USD	Annual
Sale of KAH Hospice	`NoncontrollingInterestDecreaseFromDeconsolidation`	$11.00M	USD	Annual
Acquisition	`NoncontrollingInterestIncreaseFromBusinessCombination`	$22.00M	USD	Annual
Acquisition	`NoncontrollingInterestIncreaseFromBusinessCombination`	$52.00M	USD	Annual
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-1.35B	USD	Annual
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-349.00M	USD	Annual
Other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$235.00M	USD	Annual
Common stock repurchases	`TreasuryStockValueAcquiredCostMethod`	$79.00M	USD	Annual
Common stock repurchases	`TreasuryStockValueAcquiredCostMethod`	$2.10B	USD	Annual
Common stock repurchases	`TreasuryStockValueAcquiredCostMethod`	$1.82B	USD	Annual
Dividends and dividend equivalents	`DividendsCommonStockCash`	$364.00M	USD	Annual
Dividends and dividend equivalents	`DividendsCommonStockCash`	$331.00M	USD	Annual
Dividends and dividend equivalents	`DividendsCommonStockCash`	$400.00M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$180.00M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$216.00M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$181.00M	USD	Annual
Restricted stock unit vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Restricted stock unit vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Restricted stock unit vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	Annual
Stock option exercises	`StockIssuedDuringPeriodValueStockOptionsExercised`	$61.00M	USD	Annual
Stock option exercises	`StockIssuedDuringPeriodValueStockOptionsExercised`	$31.00M	USD	Annual
Stock option exercises	`StockIssuedDuringPeriodValueStockOptionsExercised`	$51.00M	USD	Annual
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.37B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$12.04B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$16.10B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.73B	USD	Point-in-time

Comprehensive Income 30 line items

Line Item	Tag	Value	Unit	Period
Net income attributable to Humana	`NetIncomeLoss`	$3.37B	USD	Annual
Net income attributable to Humana	`NetIncomeLoss`	$2.81B	USD	Annual
Net income attributable to Humana	`NetIncomeLoss`	$2.93B	USD	Annual
Change in gross unrealized investment (losses) gains	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax`	$393.00M	USD	Annual
Change in gross unrealized investment (losses) gains	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax`	$-356.00M	USD	Annual
Change in gross unrealized investment (losses) gains	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax`	$-1.82B	USD	Annual
Effect of income taxes	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$-81.00M	USD	Annual
Effect of income taxes	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$89.00M	USD	Annual
Effect of income taxes	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax`	$-418.00M	USD	Annual
Total change in unrealized investment (losses) gains, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$304.00M	USD	Annual
Total change in unrealized investment (losses) gains, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.40B	USD	Annual
Total change in unrealized investment (losses) gains, net of tax	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-275.00M	USD	Annual
Reclassification adjustment for net realized losses (gains) included in investment income	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax`	$-72.00M	USD	Annual
Reclassification adjustment for net realized losses (gains) included in investment income	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax`	$90.00M	USD	Annual
Reclassification adjustment for net realized losses (gains) included in investment income	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax`	$103.00M	USD	Annual
Effect of income taxes	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax`	$-17.00M	USD	Annual
Effect of income taxes	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax`	$23.00M	USD	Annual
Effect of income taxes	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax`	$20.00M	USD	Annual
Total reclassification adjustment, net of tax	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax`	$80.00M	USD	Annual
Total reclassification adjustment, net of tax	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax`	$70.00M	USD	Annual
Total reclassification adjustment, net of tax	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax`	$-55.00M	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-1.35B	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$234.00M	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-355.00M	USD	Annual
Comprehensive income attributable to equity method investments	`ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments`	-	USD	Annual
Comprehensive income attributable to equity method investments	`ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments`	$1.00M	USD	Annual
Comprehensive income attributable to equity method investments	`ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments`	$6.00M	USD	Annual
Comprehensive income attributable to Humana	`ComprehensiveIncomeNetOfTax`	$1.46B	USD	Annual
Comprehensive income attributable to Humana	`ComprehensiveIncomeNetOfTax`	$3.60B	USD	Annual
Comprehensive income attributable to Humana	`ComprehensiveIncomeNetOfTax`	$2.58B	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.